Key events, in time order
Analyst reiterates Buy, raises PT to $76, confirming the beat
Company files prior approval supplement with FDA to broaden hydrocortisone oral solution indication
Q1 results show M&A-driven product revenue acceleration; company raises full-year guidance
None yet
None yet
CEO sold $6.09M in stock, the largest sale ever, following a 45% price increase. This signals potential profit-taking or a lack of confidence.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
Eton Pharmaceuticals sells niche medicines for rare diseases—think tiny patient populations like Wilson disease or adrenal insufficiency—where few alternatives exist. It's like a specialty pharmacy for conditions most big pharma ignores.
Revenue comes from selling these rare-disease drugs, with gross margins around 58% (TTM) and a recent quarter showing 30.8% net margin. The business is small—USD 0.08B annual revenue—but turning profitable after years of losses, with recurring prescription sal
Rare-disease drugs face high regulatory barriers, and Eton's portfolio covers conditions with few approved treatments, making substitution hard. However, larger players like Recordati or Cycle Pharmaceuticals could replicate or acquire similar assets, and the
